Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

clinical trial

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT01523171

P6099clinical trial phasephase II clinical trialQ42824440
P17countryCanadaQ16
SpainQ29
United States of AmericaQ30
BelgiumQ31
ItalyQ38
AustriaQ40
FranceQ142
United KingdomQ145
NetherlandsQ55
GermanyQ183
P582end time2014-04-01
P1050medical conditionchronic idiopathic myelofibrosisQ3857106
P2899minimum age18
P1132number of participants97
P8005research subject recruitment statuscompletedQ76651189
P1813short nameJAKARTA2
P859sponsorSanofiQ158205
P580start time2012-04-01
P8363study typeinterventional studyQ78089383
P1476titleA Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Search more.